Non-natural nucleic acid ligand, uses thereof, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient

Abstract

One aspect of the present disclosure relates to a novel non-natural nucleic acid ligand that binds to human serum albumin (HSA), and to uses thereof. The novel non-natural nucleic acid ligand may include the nucleic acid sequence of SEQ ID NO: 8 (CAGG6CGAGC6G6ACGCG6G6G6GACC) [wherein the moiety indicated by 6 is 5-[N-(1-naphthylmethyl)carboxamide]-2′-deoxyuridine (Nap-dU)]. Meanwhile, one aspect of the present disclosure relates to a pharmaceutical composition for treating cancer, comprising a novel non-natural nucleic acid ligand that binds to human serum albumin as an active ingredient. The pharmaceutical composition exhibits excellent effects in the treatment of cancer.

Dependencies are inferred from the claim text.